Fibroblast growth factor 19 as a countermeasure to muscle and locomotion dysfunctions in experimental cerebral palsy

Fibroblast growth factor 19 as a countermeasure to muscle and locomotion dysfunctions in experimental cerebral palsy

Abstract Background Cerebral palsy (CP) associates cerebral function damages with strong locomotor defects and premature sarcopenia. We previously showed that fibroblast growth factor 19 (FGF19) exerts hypertrophic effects on skeletal muscle and improves muscle mass and strength in mouse models with...

Full description

Bibliographic Details
Main Authors: Sabrina da Conceição Pereira, Bérengère Benoit, Francisco Carlos Amanajás deAguiar Junior, Stéphanie Chanon, Aurélie Vieille‐Marchiset, Sandra Pesenti, Jérome Ruzzin, Hubert Vidal, Ana Elisa Toscano
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:Journal of Cachexia, Sarcopenia and Muscle
Subjects:
Fibroblast growth factor 19
Cerebral palsy
Skeletal muscle
Sarcopenia
Online Access:https://doi.org/10.1002/jcsm.12819

Internet

https://doi.org/10.1002/jcsm.12819

Similar Items